Indication assessment · §3
Cognitive performance and neuroprotection — trial records
Trial records in the Institute's register bearing on cognitive performance and neuroprotection.
§3Trials in this indication
18 trial records in the Institute's register bear on this indication, of which 5 are published trials.
Table 2. Trial records bearing on cognitive performance and neuroprotection.
| Record | Compound | Phase | Design | Randomised | Year |
|---|---|---|---|---|---|
| EXENATIDE-GE-PD | Exenatide | Phase 3 | Randomised, double-blind, placebo-controlled | 194 | 2025 |
| SEMAX-RU-COGNITIVE | Semax | — | Observational | — | — |
| SEMAX-RU-STROKE | Semax | — | Observational | — | — |
| SELANK-RU-ANXIETY | Selank | — | Observational | — | — |
| GSH-PD-PH2 | Glutathione | Phase 2 | Randomised, double-blind, placebo-controlled | 45 | 2017 |
| EXENATIDE-GE-PD-DDIprogramme record | Exenatide | Phase 1 | Randomised crossover | — | 2025 |
| SEMAX-RU-COGNITIVE-QOLprogramme record | Semax | — | Randomised, double-blind, placebo-controlled | — | — |
| SEMAX-RU-STROKE-OLEprogramme record | Semax | — | Single-arm open-label | — | — |
| SELANK-RU-ANXIETY-DDIprogramme record | Selank | Phase 1 | Randomised crossover | — | — |
| GSH-PD-PH2-ELDERLYprogramme record | Glutathione | Phase 2 | Randomised, double-blind, placebo-controlled | — | 2017 |
| EXENATIDE-GE-PD-HEPATIC-IMPprogramme record | Exenatide | Phase 1 | Phase 1 ascending dose | — | 2025 |
| SEMAX-RU-STROKE-ELDERLYprogramme record | Semax | — | Randomised, double-blind, placebo-controlled | — | — |
| GSH-PD-PH2-OLEprogramme record | Glutathione | Phase 2 | Single-arm open-label | — | 2017 |
| SEMAX-RU-COGNITIVE-REGIONAL-JPprogramme record | Semax | Phase 3 | Randomised, double-blind, placebo-controlled | — | — |
| SELANK-RU-ANXIETY-RENAL-IMPprogramme record | Selank | Phase 1 | Phase 1 ascending dose | — | — |
| GSH-PD-PH2-ADHERENCEprogramme record | Glutathione | Phase 2 | Observational | — | 2017 |
| SEMAX-RU-COGNITIVE-BODY-COMPprogramme record | Semax | — | Randomised, double-blind, placebo-controlled | — | — |
| GSH-PD-PH2-BIOMARKERprogramme record | Glutathione | Phase 2 | Randomised, double-blind, placebo-controlled | — | 2017 |
| This facet in the trial register. | |||||
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- D’Hondt M, Bracke N, Taevernier L, Gevaert B, Verbeke F, Wynendaele E, De Spiegeleer B. Related impurities in peptide medicines. Journal of Pharmaceutical and Biomedical Analysis 2014;101:2–30. doi:10.1016/j.jpba.2014.06.012 · PMID 25044089
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.
Compound Evidence Institute · CEI-IN-27/3 · https://compoundevidence.com/indications/cognitive/trials/ · retrieved 30 July 2026